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760on mortality and reduced coronary events only a
modest 21% but increased abnormal liver function 6-
fold (4). Extrapolating from the 40% reduction in
coronary events with 10 mg daily of atorvastatin in
meta-analysis and the TNT ﬁndings, 80 mg would be
predicted to reduce coronary events by 47%
compared with placebo, a small additional beneﬁt, at
a price of increased side effects. The additional cor-
onary risk reduction seen with higher dose atorvas-
tatin in the TNT study is arguably redundant given
that a similar additional beneﬁt is seen with any
single antihypertensive drug, or aspirin, which pa-
tients are usually also prescribed.
The risks of statins are underestimated in recent
studies, where statin-intolerant patients were
excluded. Independent audits (5) and earlier ran-
domized clinical trials showed that adverse effects
are relatively common and include fatigue, myop-
athy, liver dysfunction (3), cerebral hemorrhage,
subtle cognitive impairment, neuropathy, renal fail-
ure (5), diabetes mellitus, and cataracts (5). Adverse
effects are dose related (5), usually appear before
cardiovascular beneﬁts are obtained and impact
negatively on quality of life, important given the
lifelong nature of statin therapy.
Statins are clearly indicated in secondary pre-
vention but have not been shown to increase
life expectancy in primary prevention. Serum
cholesterol can be elevated in patients without
coronary disease; atheroma can be difﬁcult to pre-
dict and imaging with computed tomography may
guide statin therapy. Titrating the dose against the
individual’s cholesterol response may not be reliable
given inherent variability of measurement and the
confounding effects of posture and intercurrent
illness. Excessive statin dose increases risks of side
effects and may confer little additional beneﬁt.
Closer attention to weight reduction, smoking, blood
pressure, and glucose probably reduces coronary risk
more effectively and safely.*Simon B. Dimmitt, MBBS, BMedSc(Hons)
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Limited EvidenceOur paper published in the August 12th issue of the
Journal presents 2 points of view (1). The ﬁrst author
(S.C.S., Jr.) reviewed the 2013 American College of
Cardiology/American Heart Association (ACC/AHA)
Guideline, which places priority on statin therapy
on the basis of clinical outcomes conﬁrmed by a
systematic review of randomized controlled trials.
The second author (S.G.) focused on low-density
lipoprotein cholesterol (LDL-C), the primary cause of
atherosclerotic cardiovascular disease (ASCVD).
Dr. Dimmitt and colleagues argue for moderate-
intensity statins anytime statins are indicated. They
question whether high-intensity statins are worth
added efﬁcacy compared with costs and side effects.
Regarding efﬁcacy, recent meta-analysis of second-
ary prevention trials showed that for LDL-C “the
lower, the better” for ASCVD risk reduction (2). This
analysis provides justiﬁcation for high-intensity sta-
tins when they can be given safely for most patients
with established ASCVD. In the TNT (Treat-to-New
Targets) trial, for example, atorvastatin 80 mg was
tolerated as well as atorvastatin 10 mg. In TNT, in-
cremental reduction of ASCVD events of 21% by high-
dose atorvastatin compared with moderate dose
cannot be called “modest.” High-intensity statins
thus seem justiﬁed in most patients with established
ASCVD. Unfortunately, meta-analysis (2) ﬁnds that
the majority of patients treated with high-intensity
statins do not achieve LDL-C in the range where
still greater risk reduction could be achieved. Statins
are excellent drugs but do not always maximize
the potential for risk reduction inherent in LDL-C
lowering therapy. New and efﬁcacious drugs be-
yond statins are needed.
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761The letter claims that high-dose statins are not as
well tolerated as moderate doses. The TNT trial did
not support this contention. Dimmitt et al. overstate
the harmful effects of statins. Up to 10% of patients
complain of fatigue and myalgia, but clinical myop-
athy is rare; and rhabdomyolysis and acute renal
failure are very rare. Statins may raise glucose levels
in some patients, but increased microvascular disease
has not been demonstrated; and macrovascular dis-
ease is reduced by statins. Cognitive dysfunction is
controversial. Peripheral neuropathy is very rare.
Statins do not cause chronic liver disease or chronic
kidney disease.
How best to employ statins in primary prevention
is an ongoing and not fully resolved issue. ACC/AHA
2013 guidelines (3) wisely recommend individualiza-
tion of therapy on the basis of unbiased discussion
with patients. Factors that favor statin use in primary
prevention are high-risk conditions (diabetes, meta-
bolic syndrome, chronic kidney disease, cigarette
smoking, severe hypercholesterolemia, and uncon-
trolled hypertension). Primary prevention trials
indicate “the lower, the better” for LDL-C; this is why
the guidelines favor higher doses of statins. But any
statin side effects are reversible when the drug is
stopped. Discussion of number needed to treat to
prevent ASCVD events and cardiovascular mortality
can be helpful to patients for deciding whether to
take a statin, and if so, at what dose. The importance
of treating other risk factors should be stressed.
The guidelines also recommend consideration of
additional factors such as coronary artery calciumscore, high-sensitivity C-reactive protein, ankle
brachial index, LDL-C >160, lifetime risk estimation,
and family history to further advise the patient
physician discussion. Some patients may prefer
lifestyle intervention instead of drug therapy.
Statins should be recommended cautiously in older
persons where the dangers of polypharmacy and side
effects mount. Adherence to a healthy lifestyle
should be a fundamental component of any thera-
peutic recommendations for primary or secondary
prevention of atherosclerotic vascular disease.*Sidney C. Smith, Jr, MD
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